Jonathan Samuel Hausmann, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Rheumatology | 21 | 2023 | 576 | 3.820 |
Why?
|
Hereditary Autoinflammatory Diseases | 8 | 2023 | 39 | 2.200 |
Why?
|
Rheumatic Diseases | 12 | 2023 | 592 | 1.860 |
Why?
|
Mevalonate Kinase Deficiency | 4 | 2022 | 19 | 1.280 |
Why?
|
Familial Mediterranean Fever | 4 | 2022 | 61 | 1.170 |
Why?
|
Stomatitis, Aphthous | 3 | 2023 | 53 | 1.150 |
Why?
|
Fever | 8 | 2023 | 1616 | 1.140 |
Why?
|
Lymphadenitis | 3 | 2023 | 98 | 1.110 |
Why?
|
Pharyngitis | 3 | 2023 | 215 | 1.040 |
Why?
|
Nasopharyngitis | 1 | 2023 | 10 | 0.920 |
Why?
|
Thermometers | 1 | 2018 | 46 | 0.660 |
Why?
|
Body Temperature | 1 | 2018 | 777 | 0.520 |
Why?
|
Autoimmune Diseases | 2 | 2018 | 2133 | 0.480 |
Why?
|
Health Communication | 1 | 2017 | 214 | 0.470 |
Why?
|
Musculoskeletal Diseases | 1 | 2019 | 581 | 0.460 |
Why?
|
Cryopyrin-Associated Periodic Syndromes | 2 | 2022 | 16 | 0.430 |
Why?
|
Interleukin 1 Receptor Antagonist Protein | 4 | 2022 | 297 | 0.430 |
Why?
|
Information Dissemination | 2 | 2020 | 1099 | 0.420 |
Why?
|
Pandemics | 8 | 2023 | 8388 | 0.390 |
Why?
|
Education, Medical, Graduate | 2 | 2019 | 2291 | 0.360 |
Why?
|
Goals | 1 | 2014 | 706 | 0.330 |
Why?
|
Antirheumatic Agents | 5 | 2021 | 1339 | 0.320 |
Why?
|
Arthritis, Rheumatoid | 5 | 2023 | 3712 | 0.290 |
Why?
|
Healthcare Disparities | 1 | 2021 | 3158 | 0.260 |
Why?
|
Physicians | 3 | 2023 | 4567 | 0.260 |
Why?
|
Macrophage Activation Syndrome | 2 | 2022 | 111 | 0.240 |
Why?
|
Psoriasis | 2 | 2023 | 898 | 0.240 |
Why?
|
Syndrome | 3 | 2023 | 3251 | 0.240 |
Why?
|
Cytokines | 1 | 2018 | 7322 | 0.230 |
Why?
|
Biological Products | 3 | 2023 | 860 | 0.230 |
Why?
|
Turkey | 2 | 2021 | 237 | 0.230 |
Why?
|
Colchicine | 2 | 2022 | 243 | 0.220 |
Why?
|
Registries | 10 | 2023 | 8089 | 0.220 |
Why?
|
Arthritis, Psoriatic | 2 | 2023 | 215 | 0.220 |
Why?
|
Child | 15 | 2023 | 77709 | 0.210 |
Why?
|
Fellowships and Scholarships | 2 | 2022 | 1076 | 0.210 |
Why?
|
Antibodies, Monoclonal | 1 | 2018 | 9274 | 0.200 |
Why?
|
Lupus Erythematosus, Systemic | 3 | 2022 | 2104 | 0.200 |
Why?
|
Inflammation | 2 | 2018 | 10638 | 0.190 |
Why?
|
Humans | 55 | 2023 | 744343 | 0.180 |
Why?
|
Borna Disease | 1 | 1999 | 1 | 0.180 |
Why?
|
Borna disease virus | 1 | 1999 | 2 | 0.180 |
Why?
|
Immunologic Tests | 1 | 2020 | 103 | 0.170 |
Why?
|
Myositis | 1 | 2022 | 251 | 0.170 |
Why?
|
Synovial Fluid | 1 | 2021 | 394 | 0.170 |
Why?
|
Nucleoproteins | 1 | 1999 | 115 | 0.170 |
Why?
|
Problem-Based Learning | 1 | 2022 | 361 | 0.170 |
Why?
|
Simian Acquired Immunodeficiency Syndrome | 1 | 2023 | 570 | 0.170 |
Why?
|
Lymphohistiocytosis, Hemophagocytic | 1 | 2022 | 260 | 0.160 |
Why?
|
Eosinophilia | 1 | 2023 | 541 | 0.160 |
Why?
|
Glucocorticoids | 4 | 2023 | 2107 | 0.160 |
Why?
|
Interleukin-1 | 4 | 2023 | 1263 | 0.160 |
Why?
|
Cell Polarity | 1 | 2021 | 645 | 0.160 |
Why?
|
Coronavirus Infections | 3 | 2020 | 3133 | 0.160 |
Why?
|
Pneumonia, Viral | 3 | 2020 | 3240 | 0.150 |
Why?
|
RNA, Ribosomal, 16S | 1 | 2021 | 954 | 0.150 |
Why?
|
Antipyretics | 2 | 2017 | 23 | 0.150 |
Why?
|
Exanthema | 1 | 2022 | 501 | 0.150 |
Why?
|
Immunomodulation | 1 | 2020 | 541 | 0.140 |
Why?
|
Abdominal Pain | 1 | 2023 | 1063 | 0.140 |
Why?
|
Immunoglobulins, Intravenous | 1 | 2020 | 652 | 0.140 |
Why?
|
Galactose | 1 | 2017 | 306 | 0.130 |
Why?
|
Diarrhea | 1 | 2023 | 1348 | 0.130 |
Why?
|
Gastrointestinal Hemorrhage | 1 | 2023 | 1130 | 0.130 |
Why?
|
Systemic Inflammatory Response Syndrome | 1 | 2020 | 612 | 0.130 |
Why?
|
Adolescent | 13 | 2023 | 85781 | 0.130 |
Why?
|
Privacy | 1 | 2017 | 239 | 0.120 |
Why?
|
Severity of Illness Index | 6 | 2022 | 15540 | 0.120 |
Why?
|
Osteomyelitis | 1 | 2018 | 402 | 0.120 |
Why?
|
Adrenal Cortex Hormones | 2 | 2020 | 1855 | 0.120 |
Why?
|
Adult | 19 | 2023 | 214055 | 0.120 |
Why?
|
Glycosylation | 1 | 2017 | 1126 | 0.120 |
Why?
|
Spinal Diseases | 1 | 2018 | 538 | 0.110 |
Why?
|
Antimalarials | 1 | 2020 | 905 | 0.110 |
Why?
|
Lung Diseases | 1 | 2023 | 1886 | 0.110 |
Why?
|
T-Lymphocytes | 2 | 2021 | 10180 | 0.110 |
Why?
|
Patient Care Planning | 1 | 2018 | 921 | 0.110 |
Why?
|
Male | 26 | 2023 | 350118 | 0.110 |
Why?
|
Curriculum | 2 | 2022 | 3605 | 0.110 |
Why?
|
Viral Proteins | 1 | 1999 | 1900 | 0.100 |
Why?
|
Needs Assessment | 1 | 2018 | 1147 | 0.100 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 2 | 2020 | 2282 | 0.100 |
Why?
|
Female | 25 | 2023 | 380194 | 0.100 |
Why?
|
Data Collection | 1 | 2021 | 3341 | 0.100 |
Why?
|
Young Adult | 6 | 2021 | 56430 | 0.100 |
Why?
|
Receptors, Interleukin-1 | 2 | 2022 | 262 | 0.100 |
Why?
|
Child, Preschool | 6 | 2022 | 41006 | 0.090 |
Why?
|
Hypercalcemia | 1 | 2013 | 409 | 0.090 |
Why?
|
Polysaccharides | 1 | 2017 | 1053 | 0.090 |
Why?
|
Health Services Needs and Demand | 1 | 2018 | 1411 | 0.090 |
Why?
|
Delivery of Health Care, Integrated | 1 | 2018 | 941 | 0.090 |
Why?
|
Estrogens | 1 | 2017 | 1566 | 0.090 |
Why?
|
Quality of Life | 5 | 2023 | 12804 | 0.080 |
Why?
|
Infant | 5 | 2021 | 35136 | 0.080 |
Why?
|
Internet | 1 | 2021 | 3064 | 0.080 |
Why?
|
Sports | 1 | 2014 | 688 | 0.080 |
Why?
|
Sarcoidosis | 1 | 2013 | 506 | 0.080 |
Why?
|
Middle Aged | 15 | 2022 | 213383 | 0.070 |
Why?
|
Inflammatory Bowel Diseases | 1 | 2021 | 2425 | 0.070 |
Why?
|
Hospitalization | 3 | 2021 | 10262 | 0.070 |
Why?
|
Decision Support Techniques | 1 | 2016 | 1956 | 0.070 |
Why?
|
Prednisone | 2 | 2022 | 1574 | 0.070 |
Why?
|
Biomedical Research | 1 | 2021 | 3309 | 0.060 |
Why?
|
Immunoglobulin G | 1 | 2017 | 4560 | 0.060 |
Why?
|
Evidence-Based Medicine | 1 | 2016 | 3610 | 0.060 |
Why?
|
Health Status | 1 | 2017 | 4034 | 0.060 |
Why?
|
Anti-Inflammatory Agents | 1 | 2013 | 1790 | 0.060 |
Why?
|
Attitude of Health Personnel | 1 | 2017 | 3843 | 0.050 |
Why?
|
Mutation | 3 | 2023 | 29786 | 0.050 |
Why?
|
Education, Medical | 1 | 2014 | 1721 | 0.050 |
Why?
|
Software | 1 | 2016 | 4443 | 0.050 |
Why?
|
Prednisolone | 1 | 2022 | 334 | 0.050 |
Why?
|
Spondylarthropathies | 1 | 2020 | 14 | 0.050 |
Why?
|
Iodine Radioisotopes | 1 | 2004 | 1032 | 0.050 |
Why?
|
Primary Health Care | 1 | 2017 | 4558 | 0.050 |
Why?
|
Interleukin-12 | 1 | 2023 | 579 | 0.050 |
Why?
|
Gene Expression Regulation | 1 | 2018 | 12072 | 0.050 |
Why?
|
Cross-Sectional Studies | 2 | 2021 | 25043 | 0.040 |
Why?
|
Problem Solving | 1 | 2022 | 440 | 0.040 |
Why?
|
Vaccination | 2 | 2022 | 3278 | 0.040 |
Why?
|
Tomography, Emission-Computed, Single-Photon | 1 | 2004 | 1107 | 0.040 |
Why?
|
Immunoglobulin E | 1 | 2005 | 1463 | 0.040 |
Why?
|
H-2 Antigens | 1 | 1999 | 366 | 0.040 |
Why?
|
Spain | 1 | 2020 | 465 | 0.040 |
Why?
|
Mice, Inbred CBA | 1 | 1999 | 448 | 0.040 |
Why?
|
Fibrin Fibrinogen Degradation Products | 1 | 2020 | 426 | 0.040 |
Why?
|
Cohort Studies | 1 | 2021 | 40561 | 0.040 |
Why?
|
Odds Ratio | 2 | 2021 | 9849 | 0.040 |
Why?
|
Diagnosis, Differential | 1 | 2013 | 12959 | 0.040 |
Why?
|
CD4-Positive T-Lymphocytes | 2 | 2021 | 4386 | 0.040 |
Why?
|
T-Lymphocytes, Helper-Inducer | 1 | 2023 | 986 | 0.040 |
Why?
|
CD8-Positive T-Lymphocytes | 2 | 2021 | 4479 | 0.040 |
Why?
|
Fertility Agents, Female | 1 | 2017 | 99 | 0.040 |
Why?
|
Immunophenotyping | 1 | 2021 | 1880 | 0.040 |
Why?
|
Comorbidity | 2 | 2021 | 10388 | 0.040 |
Why?
|
Goserelin | 1 | 2017 | 129 | 0.040 |
Why?
|
Retreatment | 1 | 2018 | 610 | 0.040 |
Why?
|
Retrospective Studies | 5 | 2023 | 77449 | 0.040 |
Why?
|
Pregnant Women | 1 | 2021 | 568 | 0.040 |
Why?
|
Selective Estrogen Receptor Modulators | 1 | 2017 | 129 | 0.040 |
Why?
|
Th1 Cells | 1 | 2021 | 1057 | 0.030 |
Why?
|
Vasculitis | 1 | 2020 | 519 | 0.030 |
Why?
|
Hypersensitivity | 1 | 2005 | 1102 | 0.030 |
Why?
|
Social Class | 1 | 2005 | 1999 | 0.030 |
Why?
|
Histamine H2 Antagonists | 1 | 2017 | 165 | 0.030 |
Why?
|
United States | 5 | 2022 | 69872 | 0.030 |
Why?
|
Mucocutaneous Lymph Node Syndrome | 1 | 2020 | 546 | 0.030 |
Why?
|
Estrogens, Conjugated (USP) | 1 | 2017 | 275 | 0.030 |
Why?
|
Antigens, Viral | 1 | 1999 | 1035 | 0.030 |
Why?
|
Leuprolide | 1 | 2017 | 321 | 0.030 |
Why?
|
Internationality | 1 | 2021 | 1003 | 0.030 |
Why?
|
Interleukin-10 | 1 | 2020 | 1200 | 0.030 |
Why?
|
Aged | 7 | 2022 | 163280 | 0.030 |
Why?
|
Medical Errors | 1 | 2003 | 1297 | 0.030 |
Why?
|
Autoantibodies | 1 | 2023 | 2035 | 0.030 |
Why?
|
Personnel Staffing and Scheduling | 1 | 2018 | 501 | 0.030 |
Why?
|
Tonsillectomy | 1 | 2017 | 255 | 0.030 |
Why?
|
International Cooperation | 1 | 2020 | 1420 | 0.030 |
Why?
|
Nephrocalcinosis | 1 | 2013 | 48 | 0.030 |
Why?
|
Sequence Analysis, RNA | 1 | 2021 | 2012 | 0.030 |
Why?
|
Age of Onset | 1 | 2020 | 3271 | 0.030 |
Why?
|
Aromatase Inhibitors | 1 | 2017 | 491 | 0.030 |
Why?
|
Premenopause | 1 | 2017 | 1033 | 0.030 |
Why?
|
Carcinoma | 1 | 2004 | 2375 | 0.030 |
Why?
|
Natriuretic Peptide, Brain | 1 | 2020 | 1573 | 0.030 |
Why?
|
Treatment Failure | 1 | 2018 | 2618 | 0.030 |
Why?
|
Specialization | 1 | 2017 | 777 | 0.030 |
Why?
|
Lymphatic Diseases | 1 | 2013 | 324 | 0.030 |
Why?
|
Osteogenesis Imperfecta | 1 | 1992 | 83 | 0.020 |
Why?
|
Risk Factors | 3 | 2023 | 72290 | 0.020 |
Why?
|
Drug Therapy, Combination | 1 | 2021 | 6489 | 0.020 |
Why?
|
Self Report | 1 | 2022 | 3558 | 0.020 |
Why?
|
Single-Cell Analysis | 1 | 2021 | 2183 | 0.020 |
Why?
|
Thyroid Neoplasms | 1 | 2004 | 2282 | 0.020 |
Why?
|
Cost of Illness | 1 | 2020 | 1859 | 0.020 |
Why?
|
Interleukin-6 | 1 | 2020 | 3200 | 0.020 |
Why?
|
Gonadotropin-Releasing Hormone | 1 | 2017 | 1205 | 0.020 |
Why?
|
C-Reactive Protein | 1 | 2022 | 3778 | 0.020 |
Why?
|
Up-Regulation | 1 | 1999 | 4217 | 0.020 |
Why?
|
Public Health | 1 | 2003 | 2603 | 0.020 |
Why?
|
Respiration, Artificial | 1 | 2021 | 2569 | 0.020 |
Why?
|
Health Care Surveys | 1 | 2017 | 2453 | 0.020 |
Why?
|
Diagnostic Errors | 1 | 2016 | 1257 | 0.020 |
Why?
|
B-Lymphocytes | 1 | 2023 | 4665 | 0.020 |
Why?
|
Estradiol | 1 | 2017 | 2020 | 0.020 |
Why?
|
Androgens | 1 | 2017 | 1281 | 0.020 |
Why?
|
Consensus | 1 | 2018 | 2959 | 0.020 |
Why?
|
Forecasting | 1 | 2018 | 2951 | 0.020 |
Why?
|
Immunity, Innate | 1 | 2020 | 2958 | 0.020 |
Why?
|
Postmenopause | 1 | 2017 | 2461 | 0.020 |
Why?
|
T-Lymphocytes, Regulatory | 1 | 2021 | 2988 | 0.020 |
Why?
|
DNA Methylation | 1 | 2021 | 4286 | 0.020 |
Why?
|
Research Design | 1 | 2003 | 5987 | 0.020 |
Why?
|
Treatment Outcome | 3 | 2022 | 63114 | 0.020 |
Why?
|
Radiography, Thoracic | 1 | 2013 | 1265 | 0.020 |
Why?
|
Guideline Adherence | 1 | 2017 | 2266 | 0.020 |
Why?
|
Multivariate Analysis | 1 | 2020 | 12245 | 0.020 |
Why?
|
Testosterone | 1 | 2017 | 2420 | 0.020 |
Why?
|
Incidence | 1 | 2023 | 20947 | 0.020 |
Why?
|
Glycosaminoglycans | 1 | 1988 | 624 | 0.020 |
Why?
|
Boston | 1 | 2016 | 9313 | 0.010 |
Why?
|
Case-Control Studies | 1 | 2021 | 21746 | 0.010 |
Why?
|
Collagen | 1 | 1992 | 2689 | 0.010 |
Why?
|
Sex Factors | 1 | 2017 | 10397 | 0.010 |
Why?
|
Adenoma, Oxyphilic | 1 | 2004 | 143 | 0.010 |
Why?
|
Systems Integration | 1 | 2004 | 440 | 0.010 |
Why?
|
Animals, Newborn | 1 | 1988 | 2726 | 0.010 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2017 | 3923 | 0.010 |
Why?
|
Mice, Inbred C57BL | 1 | 1999 | 21827 | 0.010 |
Why?
|
Genetic Variation | 1 | 2016 | 6544 | 0.010 |
Why?
|
Infant, Newborn | 1 | 2021 | 25625 | 0.010 |
Why?
|
Muscle, Smooth, Vascular | 1 | 1988 | 1504 | 0.010 |
Why?
|
Subtraction Technique | 1 | 2004 | 525 | 0.010 |
Why?
|
Tomography, X-Ray Computed | 1 | 2004 | 20129 | 0.010 |
Why?
|
Bone and Bones | 1 | 1992 | 2575 | 0.010 |
Why?
|
Predictive Value of Tests | 1 | 2017 | 15076 | 0.010 |
Why?
|
Calcium | 1 | 2013 | 5756 | 0.010 |
Why?
|
Animals | 3 | 2023 | 168757 | 0.010 |
Why?
|
Practice Guidelines as Topic | 1 | 2017 | 7279 | 0.010 |
Why?
|
Pregnancy | 1 | 2021 | 29144 | 0.010 |
Why?
|
Phenotype | 1 | 2016 | 16365 | 0.010 |
Why?
|
Time Factors | 2 | 2018 | 40075 | 0.010 |
Why?
|
Prospective Studies | 1 | 2022 | 53288 | 0.010 |
Why?
|
Prognosis | 1 | 2018 | 29063 | 0.010 |
Why?
|
Aged, 80 and over | 1 | 2022 | 57776 | 0.010 |
Why?
|
Risk Assessment | 1 | 2018 | 23338 | 0.010 |
Why?
|
Lymphatic Metastasis | 1 | 2004 | 2924 | 0.010 |
Why?
|
Radiopharmaceuticals | 1 | 2004 | 2645 | 0.010 |
Why?
|
Cyanogen Bromide | 1 | 1992 | 73 | 0.010 |
Why?
|
Mice | 1 | 1999 | 81183 | 0.010 |
Why?
|
Electrophoresis, Polyacrylamide Gel | 1 | 1992 | 1801 | 0.010 |
Why?
|
Sensitivity and Specificity | 1 | 2004 | 14722 | 0.010 |
Why?
|
Dermatan Sulfate | 1 | 1988 | 35 | 0.000 |
Why?
|
Prevalence | 1 | 2005 | 15226 | 0.000 |
Why?
|
Chondroitin Sulfates | 1 | 1988 | 187 | 0.000 |
Why?
|
Heparitin Sulfate | 1 | 1988 | 225 | 0.000 |
Why?
|
Rats, Inbred Strains | 1 | 1988 | 2186 | 0.000 |
Why?
|
Reproducibility of Results | 1 | 2004 | 19905 | 0.000 |
Why?
|
Ascorbic Acid | 1 | 1988 | 651 | 0.000 |
Why?
|
Follow-Up Studies | 1 | 2004 | 39050 | 0.000 |
Why?
|
Aorta | 1 | 1988 | 2061 | 0.000 |
Why?
|
Skin | 1 | 1992 | 4364 | 0.000 |
Why?
|
Cells, Cultured | 1 | 1988 | 19229 | 0.000 |
Why?
|
Rats | 1 | 1988 | 24260 | 0.000 |
Why?
|